ClinicalTrials.gg
CompletedNCT04533399Updated Feb 17, 2022

A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults

A Phase 2 interventional study of SARS-CoV-2 rS/Matrix-M1 Adjuvant and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by Novavax. Completed at 14 sites in South Africa. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-17.

Sponsored by Novavax · Phase 2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4,422
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
4th of 18
4,422 · median 997
Started
2020
with 3 others
Phase 2
3 of 18
none open now
Registered
2nd of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 4th largest by enrollment, is one of 4 that started in 2020, is one of 3 in phase 2, and was the 2nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

This is a study to evaluate the effectiveness and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in a minimum of approximately 2,960 to a maximum of approximately 4,164 healthy HIV-negative (HIV-) adult participants and in approximately 240 medically stable HIV-positive (HIV+) adult participants in up to 15 sites across South Africa. A vaccine causes the body to have an immune response that may help prevent the infection or reduce the severity of symptoms. An adjuvant is something that can make a vaccine work better. This study will look at the protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1 adjuvant in these study populations. Participants in the study will randomly be assigned to receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will receive a total of 2 intramuscular injections over the course of the study.

03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • Coronavirus
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  • Adult male and female aged ≥ 18 to \< 65 years at screening for Cohorts 1 and 2 and Adult male or female aged ≥ 65 to \< 85 years at screening for Cohort 1 only.
  • (BMI) of 17 to 40 kg/m².
  • Provides prior to study participation and is willing to comply with study procedures, including potential home visits.
  • Women of must agree not to have sexual intercourse with men, or must consistently use an agreed method of from at least 21 days prior to enrolment in the study, through 6 months after the last vaccination.

-negative subjects only:

  • Documentation of HIV-negative test result by a method approved in South Africa.
  • Healthy at study screening, as determined by the investigator.

HIV-positive subjects only:

  • Documentation of HIV-positive test result by a method approved in South Africa.
  • Receiving highly active antiretroviral therapy (HAART) and has been using the same regimen for at least 8 weeks before screening. Changes in antiretroviral dosage within 8 weeks of entering the study are allowed, as are exchanges in pharmacological formulations.
  • Medically stable at screening, as determined by the investigator, and free of opportunistic infections in the 1 year prior to first study vaccination.
  • Have a HIV-1 viral load \< 1000 copies/mL within 45 days of randomization in the study.

Exclusion criteria

Exclusion Criteria:

  • Any current acute illness requiring medical or surgical care, or chronic illness (excluding in HIV-positive subjects) that requires changes in medication in the past 2 months indicating that chronic illness/disease is not stable.
  • Chronic disease, including:

    1. Hypertension (elevated blood pressure [BP]) ≥ grade 2 (systolic BP ≥ 160 mmHg; and/or diastolic BP ≥ 100 mmHg) according to the South African Hypertension Society's Practice Guidelines. NOTE: Hypertension [elevated BP] ≤ grade 1 (systolic BP ≤ 159 mmHg; diastolic BP ≤ 99 mmHg) according to the South African Hypertension Society's Practice Guidelines is NOT exclusionary;
    2. Congestive heart failure with a history of an acute exacerbation of any severity in the prior 2 years;
    3. (COPD) with a history of an acute exacerbation of any severity in the past 2 years;
    4. Evidence of unstable coronary artery disease in the past 3 months, as determined by the investigator; NOTE: Stable coronary heart disease is NOT exclusionary.
    5. Asthma requiring regular/chronic control medication (eg, short-acting beta2-agonist [SABA] > 2 days per week; or any chronic use of inhaled [ICS], long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], or oral corticosteroids), and/or worsening of asthma symptoms in the past 3 months; NOTE: Asthma not requiring regular/chronic control medication, and not requiring SABA > 2 days per week, and not demonstrating worsening of symptoms in the past 3 months, will NOT be excluded.
    6. Type 1 or 2 diabetes (adult onset) requiring treatment with insulin; NOTE: Non-insulin dependent type 2 diabetes is NOT exclusionary.
    7. Chronic kidney disease/renal insufficiency;
    8. Chronic gastrointestinal and hepatic diseases;
    9. Chronic neurological diseases (such as multiple sclerosis, dementia, , Parkinson's disease, degenerative neurological conditions, neuropathy, or epilepsy), or a history of stroke within 12 months with residual symptoms, or previous neurological disorder within 12 months with residual symptoms; NOTE: History of migraine or chronic headaches, or nerve root compression that have been stable on treatment for the last 4 weeks are NOT exclusionary.
  • Participation in research involving an product (drug/biologic/device) within 45 days prior to first study vaccination.
  • Prior receipt of investigational or approved COVID-19 vaccine at any time.
  • History of a diagnosis of suspected or confirmed COVID-19.
  • Received influenza (flu) vaccination within 14 days prior to first study vaccination; or any other vaccine within 4 weeks prior to first study vaccination; or planned vaccination with 5 weeks after first study vaccination.
  • Any or immunodeficiency disease/condition (excluding HIV in HIV-positive patients).
  • Chronic (more than 14 days continuous) administration of , systemic glucocorticosteroids, or other immune-modifying drugs within 90 days prior to first study vaccination (excluding HAART in HIV-positive subjects). NOTE: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination (excluding HAART in HIV-positive subjects).
  • Acute respiratory and/or non-respiratory illness consistent with potential COVID-19, concurrent with or within 14 days prior to first study vaccination, or documented temperature of > 38°C during this period.
  • Known blood clotting disorder.
  • Active cancer () within 3 years prior to first study vaccination (with the exception of adequately treated non-melanoma skin cancers, as assessed by the investigator).
  • Any known allergies to products contained in the investigational product, or latex allergy, or any history of anaphylaxis in relation to any previous vaccination.
  • Women who are breastfeeding or who are pregnant at the time of screening, or plan to become pregnant within the first 6 months of the study.
  • History of alcohol abuse or drug addiction within 2 years prior to the first study vaccination.
  • Any condition (other than HIV in HIV-positive subjects) that, in the opinion of the investigator, would pose a health risk to the subject if they participate in the study, or could interfere with evaluation of the study vaccine or interpretation of study results.
  • Study team member or first-degree relative of any study member.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,422 participants (actual)

Study arms

  • Experimental
    Cohort 1 (HIV negative) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant

    2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.

    Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant

  • Placebo comparator
    Cohort 1 (HIV negative) Placebo

    2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.

    Other: Placebo

  • Experimental
    Cohort 2 (HIV positive) 5 μg SARS-CoV-2 rS/Matrix-M1 Adjuvant

    2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.

    Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant

  • Placebo comparator
    Cohort 2 (HIV positive) Placebo

    2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.

    Other: Placebo

Interventions

  • BiologicalSARS-CoV-2 rS/Matrix-M1 Adjuvant

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.

    Also known as: NVX-CoV2373

  • OtherPlacebo

    Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.

    Also known as: Sodium chloride 0.9% (BP, sterile)

06

What researchers measure

Primary outcomes

  1. Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19

    Number of human immunodeficiency virus negative (HIV-) participants with first occurrence of positive (+) polymerase chain reaction (PCR), (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 assessed from Day 28 (7 days after second vaccination dose) through the length of the study.

    Time frame: Day 28 to Day 386

  2. Cohort 2: HIV + Participants with Symptomatic Mild, Moderate, or Severe COVID-19

    Number of HIV+ participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with symptomatic mild,moderate or severe COVID-19 assessed from Day 28 (7 days after second vaccination) through the length of the study.

    Time frame: Day 28 to Day 386

  3. Cohort 1: HIV- Participants with Solicited Adverse Events (AEs)

    Number of HIV- participants with solicited AEs, local and systemic, for 7 days following each vaccination (Days 0 and 21) by severity score, duration, and peak intensity.

    Time frame: 28 days

  4. Cohort 1: HIV- Participants with Unsolicited AEs

    Number of HIV- participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, MAAEs) through Day 35 by Medical Dictionary for Regulatory Activities (MedDRA) classification, severity score, and relatedness.

    Time frame: 35 days

  5. Cohort 2: HIV+ Participants with Solicited AEs

    Number of HIV+ participants with solicited AEs, local and systemic, for 7 days following each vaccination (Days 0 and 21) by severity score, duration, and peak intensity.

    Time frame: 28 days

  6. Cohort 2: HIV+ Participants with Unsolicited AEs

    Number of HIV+ participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, MAAEs) through Day 35 by MedDRA classification, severity score, and relatedness.

    Time frame: 35 days

  7. Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs)

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs at Day 35.

    Time frame: Day 35

  8. Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs)

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Day 35.

    Time frame: Day 35

  9. Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs)

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCR at Day 35. SCR is defined as the percentage of participants with a post-vaccination titer ≥ 4 fold over naïve background and ≥ 2 fold over pre existing titer.

    Time frame: Day 35

  10. Healthcare Worker Expansion (Cohort 3): Participants with AESI's

    Number of healthy adult HCW, with AESIs for 14 days post second vaccination (Day 35) by severity score, duration, and peak intensity.

    Time frame: Day 35

  11. Healthcare Worker Expansion (Cohort 4): Participants with AESI's

    Number of healthy adult HCW, with AESIs for 14 days post second vaccination (Day 70) by severity score, duration, and peak intensity.

    Time frame: Day 70

Secondary outcomes

  1. Cohort 1: HIV- Participants with Individual Strata of Symptomatic Virologically Confirmed, Mild, Moderate, or Severe COVID-19

    Number of HIV- participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness in terms of individual strata of symptomatic virologically confirmed, mild, moderate, or severe COVID-19.

    Time frame: Day 28 to Day 386

  2. Cohort 1: HIV- Participants with COVID-19 Requiring Hospitalization

    Number of HIV- participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with COVID-19 requiring hospitalization.

    Time frame: Day 28 to Day 386

  3. Cohort 1: Incidence, Maximum Severity Score, and Symptom Duration of SARS-CoV-2 Infection by Severity Classification

    Incidence, maximum severity score, and symptom duration of SARS-CoV-2 infection by classification of symptomatic virologically confirmed, mild, moderate, and/or severe disease in HIV- participants.

    Time frame: Day 28 to Day 386

  4. Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMTs

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV- participants.

    Time frame: Day 0 to 6 months after the last vaccination

  5. Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMFRs

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV- participants.

    Time frame: Day 0 to 6 months after the last vaccination

  6. Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as SCRs

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV- participants. SCR is defined as the percentage of participants with a post-vaccination titer ≥ 4 fold over naïve background and ≥ 2 fold over pre-existing titer.

    Time frame: Day 0 to 6 months after the last vaccination

  7. Cohort 1: Angiotensin-Converting Enzyme 2 (ACE2) Receptor Binding Inhibition Assay Expressed as GMTs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMTs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.

    Time frame: Day 0 to 6 months after the last vaccination

  8. Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMFRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.

    Time frame: Day 0 to 6 months after the last vaccination

  9. Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as SCRs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SCRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.

    Time frame: Day 0 to 6 months after the last vaccination

  10. Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as Seroresponse Rates (SRRs)

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SRRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants. SRR is defined as the proportion of participants with rises in titers exceeding the 95th percentile of placebo participants at the same time point and based on prior SARS-CoV-2 exposure.

    Time frame: Day 0 to 6 months after the last vaccination

  11. Cohort 1: Neutralizing Antibody Activity Expressed as GMTs

    Neutralizing antibody activity as detected by microneutralization assay (MN) as expressed as GMTs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.

    Time frame: Day 0 to 6 months after the last vaccination

  12. Cohort 1: Neutralizing Antibody Activity Expressed as GMFRs

    Neutralizing antibody activity as detected by MN expressed as GMFRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV-participants.

    Time frame: Day 0 to 6 months after the last vaccination

  13. Cohort 1: Neutralizing Antibody Activity Expressed as SCRs

    Neutralizing antibody activity as detected by MN expressed as SCRs (≥ 4 fold change) at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.

    Time frame: Day 0 to 6 months after the last vaccination

  14. Cohort 1: Neutralizing Antibody Activity Expressed as SRRs

    Neutralizing antibody activity as detected by MN expressed as SRRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV-participants.

    Time frame: Day 0 to 6 months after the last vaccination

  15. Cohort 1: HIV- Participants with Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs)

    Numbers and percentages (with 95% CI) of participants with MAAEs, AESI, or SAE through End of Study by MedDRA classification, severity score, and relatedness in HIV- participants.

    Time frame: 386 days

  16. Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMTs

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  17. Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMFRs

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  18. Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as SCRs

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV+ participants. SCR is defined as the percentage of participants with a post-vaccination titer ≥ 4 fold over naïve background and ≥ 2 fold over pre-existing titer.

    Time frame: Day 0 to 6 months after the last vaccination

  19. Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as GMTs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMTs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  20. Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMFRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  21. Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as SCRs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SCRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  22. Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as SRRs

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SRRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants. SRR is defined as the proportion of participants with rises in titers exceeding the 95th percentile of placebo participants at the same time point and based on prior SARS-CoV-2 exposure.

    Time frame: Day 0 to 6 months after the last vaccination

  23. Cohort 2: Neutralizing Antibody Activity Expressed as GMTs

    Neutralizing antibody activity as detected by MN as expressed as GMTs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  24. Cohort 2: Neutralizing Antibody Activity Expressed as GMFRs

    Neutralizing antibody activity as detected by MN expressed as GMFRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  25. Cohort 2: Neutralizing Antibody Activity Expressed as SCRs

    Neutralizing antibody activity as detected by MN expressed as SCRs (≥ 4 fold change) at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  26. Cohort 2: Neutralizing Antibody Activity Expressed as SRRs

    Neutralizing antibody activity as detected by MN expressed as SRRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.

    Time frame: Day 0 to 6 months after the last vaccination

  27. Cohort 2: HIV+ Participants with MAAEs, AESIs, and SAEs

    Number of participants with MAAEs, AESI, or SAE through End of Study by MedDRA classification, severity score, and relatedness in HIV+ participants.

    Time frame: 386 days

  28. Cohort 2: HIV+ Participants with Symptomatic Virologically Confirmed, Mild, Moderate, or Severe COVID-19

    Counts and proportions of symptomatic virologically confirmed, mild, moderate, and severe COVID-19 outcomes in HIV+ participants as previously described in the second primary efficacy endpoint for Cohort 1 (HIV- participants).

    Time frame: Day 28 to Day 385

  29. Cohort 2: Incidence, Maximum Severity Score, and Symptom Duration of SARS-CoV-2 Infection by Severity Classification

    Incidence, maximum severity score, and symptom duration of SARS-CoV-2 infection by classification of symptomatic virologically confirmed, mild, moderate, and/or severe disease in HIV+ participants.

    Time frame: Day 28 to Day 385

  30. Cohort 1: HIV- Participants with Asymptomatic, Symptomatic Mild, Moderate, or Severe COVID-19

    Number of HIV- participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with asymptomatic, symptomatic mild, moderate or severe COVID-19 assessed from 7 days after the second vaccine dose (eg, Day 28)

    Time frame: Day 28

  31. Cohort 2: HIV+ Participants with Asymptomatic, Symptomatic Mild, Moderate, or Severe COVID-19

    Number of HIV+ participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with asymptomatic, symptomatic mild, moderate or severe COVID-19 assessed from 7 days after the second vaccine dose (eg, Day 28)

    Time frame: Day 28

  32. Healthcare Worker Expansion (Cohort 3): Serum IgG Antibody Expressed as GMT

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA using GMTs at 14 days post second vaccination (Day 35 for Cohort 3) in adult HCW.

    Time frame: Day 35

  33. Healthcare Worker Expansion (Cohort 3): Serum IgG Antibody Expressed as GMEU

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA expressed as GMEU at 14 days post second vaccination (Day 35 for Cohort 3) in adult HCW.

    Time frame: Day 35

  34. Healthcare Worker Expansion (Cohort 3): Serum IgG Antibody Expressed as GMFR

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA expressed as GMFR at 14 days post second vaccination (Day 35 for Cohort 3) in adult HCW.

    Time frame: Day 35

  35. Healthcare Worker Expansion (Cohort 3): Serum IgG Antibody Expressed as SCR

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA expressed as SCR at 14 days post second vaccination (Day 35 for Cohort 3) in adult HCW.

    Time frame: Day 35

  36. Healthcare Worker Expansion (Cohort 4): Serum IgG Antibody Expressed as GMT

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA expressed as GMT at 14 days post second vaccination (Day 70 for Cohort 4) in adult HCW.

    Time frame: Day 70

  37. Healthcare Worker Expansion (Cohort 4): Serum IgG Antibody Expressed as GMEU

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA expressed as GMEU at 14 days post second vaccination (Day 70 for Cohort 4) in adult HCW.

    Time frame: Day 70

  38. Healthcare Worker Expansion (Cohort 4): Serum IgG Antibody Expressed as GMFR

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA expressed as GMFR at 14 days post second vaccination (Day 70 for Cohort 4) in adult HCW.

    Time frame: Day 70

  39. Healthcare Worker Expansion (Cohort 4): Serum IgG Antibody Expressed as SCR

    Serum IgG antibody levels specific for the SARS CoV 2 rS protein antigen(s) as detected by ELISA expressed as SCR at 14 days post second vaccination (Day 70 for Cohort 4) in adult HCW.

    Time frame: Day 70

07

Study locations

14 sites
  • ZA018
    Bloemfontein, Free State Of South Africa, South Africa
  • ZA003
    Hillbrow, Gauteng, South Africa
  • Site ZA001
    Johannesburg, Gauteng, South Africa
  • ZA012
    Johannesburg, Gauteng, South Africa
  • Site ZA015
    Pretoria, Gauteng, South Africa
  • ZA023
    Pretoria, Gauteng, South Africa
  • ZA019
    Durban, KwaZulu-Natal, South Africa
  • ZA020
    Durban, KwaZulu-Natal, South Africa
  • ZA021
    Durban, KwaZulu-Natal, South Africa
  • ZA024
    Durban, KwaZulu-Natal, South Africa
  • ZA007
    Thabazimbi, Limpopo, South Africa
  • ZA022
    Madibeng, North-West, South Africa
  • ZA013
    Cape Town, Western Cape, South Africa
  • ZA014
    Worcester, Western Cape, South Africa
08

References and documents

Publications

  • Madhi SA, Moodley D, Hanley S, Archary M, Hoosain Z, Lalloo U, Louw C, Fairlie L, Fouche LF, Masilela MSL, Singh N, Grobbelaar C, Ahmed K, Benade G, Bhikha S, Bhorat AE, Bhorat Q, Joseph N, Dheda K, Esmail A, Foulkes S, Goga A, Oommen Jose A, Kruger G, Kalonji DJ, Lalloo N, Lombaard JJ, Lombard Koen A, Kany Luabeya A, Mngqibisa R, Petrick FG, Pitsi A, Tameris M, Thombrayil A, Vollgraaff PL, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Fries L, Robertson A, Neal S, Cho I, Glenn GM, Shinde V; 2019nCoV-501 Study Group. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022 May;9(5):e309-e322. doi: 10.1016/S2352-3018(22)00041-8. PubMed 35489376 ↗
  • Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, Fouche L, Louw C, Tameris M, Singh N, Goga A, Dheda K, Grobbelaar C, Kruger G, Carrim-Ganey N, Baillie V, de Oliveira T, Lombard Koen A, Lombaard JJ, Mngqibisa R, Bhorat AE, Benade G, Lalloo N, Pitsi A, Vollgraaff PL, Luabeya A, Esmail A, Petrick FG, Oommen-Jose A, Foulkes S, Ahmed K, Thombrayil A, Fries L, Cloney-Clark S, Zhu M, Bennett C, Albert G, Faust E, Plested JS, Robertson A, Neal S, Cho I, Glenn GM, Dubovsky F, Madhi SA; 2019nCoV-501 Study Group. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5. PubMed 33951374 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Dec 2021, 15 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 15 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2020
First posted
Aug 31, 2020
StartActual
Aug 17, 2020
Primary completionActual
Dec 7, 2021
CompletionActual
Jan 19, 2022
Last update
Feb 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04533399
Lead sponsor
Novavax
Collaborators
Bill and Melinda Gates Foundation
Responsible party
Sponsor
First posted
Aug 31, 2020
Start date
Aug 17, 2020
Primary completion
Dec 7, 2021
Completion
Jan 19, 2022
Last update
Feb 17, 2022

Study contacts

Clinical Development
study director · Novavax, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion